Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci144 Single Ascending Dose Study in Healthy Adults
NCT07685210Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in phenylketonuria (PKU) comparing GenSci144 single-dose group with Matched placebo single-dose group (2 arms). Primary endpoints: Adverse Events and Change in QT/QTc interval correction. Started Jun 2026; status: recruiting.
02
Drugs
GS144
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07685210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685210.